MRK ▲ +0.9% - Merck & Co., Inc.
$MRK Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
09-NOV-2026 01:07 PM ET
Share this post
More filings for $MRK
MRK ▲ +1.2% - Merck & Co., Inc.Nov 9, 2026MRK ▼ -0.5% - Merck & Co., Inc.Nov 3, 2026MRK ▲ +2.8% - Merck & Co., Inc.Oct 29, 2026MRK ▼ -2.4% - Merck & Co., Inc.Oct 26, 2026MRK ▼ -1.9% - Merck & Co., Inc.Oct 23, 2026MRK ▼ -0.9% - Merck & Co., Inc.Oct 22, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment